Cargando…

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer

Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the requirement for the development of more effective AR targeting therapies. A key mechanism of resistance to anti-androgens is through expression of constitutively active AR variants (AR-Vs) that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Dominic, Wade, Mark, Nakjang, Sirintra, Chaytor, Lewis, Grey, James, Robson, Craig N., Gaughan, Luke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745762/ https://www.ncbi.nlm.nih.gov/pubmed/26336819

Ejemplares similares

Differential regulation of the androgen receptor by protein phosphatase regulatory subunits
por: Grey, James, et al.
Publicado: (2017)

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy
por: O'Neill, Daniel, et al.
Publicado: (2015)

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
por: Kounatidou, Evangelia, et al.
Publicado: (2019)

Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity
por: McClurg, Urszula L., et al.
Publicado: (2017)

Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
por: Jones, Dominic, et al.
Publicado: (2017)

The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival
por: McClurg, Urszula L., et al.
Publicado: (2018)

CDC20 Is Regulated by the Histone Methyltransferase, KMT5A, in Castration-Resistant Prostate Cancer
por: Alebady, Zainab A. H., et al.
Publicado: (2023)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells
por: Logan, Ian R., et al.
Publicado: (2016)

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
por: Liu, Wei, et al.
Publicado: (2021)

Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer
por: Zhao, Yu, et al.
Publicado: (2014)

Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer
por: Yang, Yeqing Angela, et al.
Publicado: (2015)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
por: Gaughan, Luke, et al.
Publicado: (2005)

Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer
por: Titus, Mark A., et al.
Publicado: (2012)

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2016)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2023)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
por: Pollock, Julie A., et al.
Publicado: (2016)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Correction to ‘Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation’
por: Gaughan, Luke, et al.
Publicado: (2021)

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
por: Hörnberg, Emma, et al.
Publicado: (2011)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
por: Ma, Tianfang, et al.
Publicado: (2021)

Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients
por: Wang, Chao, et al.
Publicado: (2022)

Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
por: Chirra, Martina, et al.
Publicado: (2019)

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer
por: Hung, Chiu-Lien, et al.
Publicado: (2023)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
por: Kobayashi, Takashi, et al.
Publicado: (2013)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
por: Lallous, Nada, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_32afbevff2qj4bnfeii79pvqcu